2018 Annual Meeting | N6 - Neuroscience in the Clinic: Neurologic Complications of Cancer Immunotherapy: A New Frontier in Neuro-Inflammation
| 03:30 PM - 03:35 PM | Luncheon |
Introduction on Cancer Immunotherapy
Antonio M. Omuro, MD, FAAN |
| 03:30 PM - 05:30 PM | Abstract |
001 - Neurologic immune related adverse events (irAEs) in patients with metastatic solid tumors treated with immune checkpoint inhibitors: a single institution retrospective analysis
Rachna Malani, MD |
| 03:30 PM - 05:30 PM | Abstract |
002 - Immune-mediated necrotizing myositis in patients receiving immune checkpoint inhibitors: clinical and histopathological features, treatment and outcome
Mehdi Touat, MD |
| 03:35 PM - 03:40 PM | Speaker |
Case Presentation
Bianca Santomasso, MD |
| 03:40 PM - 04:10 PM | Speaker |
Neuroscience Background: The Peripheral and CNS Immune System: Physiology and Effects of Anti-Cancer Immunotherapies
David A. Hafler, MD, FAAN |
| 04:10 PM - 04:30 PM | Speaker |
Clinical Implications
Bianca Santomasso, MD |
| 04:30 PM - 04:40 PM | Closing Remarks |
Future Directions
Antonio M. Omuro, MD, FAAN |
| 04:40 PM - 04:55 PM | Speaker |
N6.001: Neurologic immune related adverse events (irAEs) in patients with metastatic solid tumors treated with immune checkpoint inhibitors: a single institution retrospective analysis
Rachna Malani, MD |
| 04:55 PM - 05:10 PM | Speaker |
N6.002: Immune-mediated necrotizing myositis in patients receiving immune checkpoint inhibitors: clinical and histopathological features, treatment and outcome
Mehdi Touat, MD |
| 05:10 PM - 05:25 PM | Speaker |
Abstracts Discussion and Implications for Clinical Practice
Andreas F. Hottinger, MD |
| 05:25 PM - 05:30 PM | Speaker |
Panel Discussion/Questions and Answers
|
| Antonio M. Omuro, MD, FAAN | Dr. Omuro has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono Therapeutics. Dr. Omuro has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Telix. Dr. Omuro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Curevac. The institution of Dr. Omuro has received research support from NIH. The institution of Dr. Omuro has received research support from Arcus Biosciences. The institution of Dr. Omuro has received research support from Denovo Biopharma. The institution of Dr. Omuro has received research support from Ono Pharmaceutical. The institution of Dr. Omuro has received research support from Servier. The institution of Dr. Omuro has received research support from Nanopharmaceuticals. The institution of Dr. Omuro has received research support from Denovo. |
| Andreas F. Hottinger, MD | The institution of Dr. Hottinger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for novocure. The institution of Dr. Hottinger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. The institution of Dr. Hottinger has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novocure. |
| David A. Hafler, MD, FAAN | Dr. Hafler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Hafler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genetech. Dr. Hafler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Hafler has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Joint Commission International. |
| Bianca Santomasso, MD | Dr. Santomasso has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Janssen/Johnson & Johnson. Dr. Santomasso has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol-Myers Squibb. Dr. Santomasso has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kite/Gilead. Dr. Santomasso has received personal compensation in the range of $500-$4,999 for serving as a Consultant for In8bio. Dr. Santomasso has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for In8bio. Dr. Santomasso has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen Pharmaceuticals. Dr. Santomasso has received personal compensation in the range of $500-$4,999 for serving as a Committee Member Activity with National Comprehensive Cancer Network. |
| Mehdi Touat, MD | Dr. Touat has received personal compensation in the range of $500-$4,999 for serving as a Consultant for servier. Dr. Touat has received personal compensation in the range of $500-$4,999 for serving as a Consultant for novocure. Dr. Touat has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for servier. Dr. Touat has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for novocure. The institution of Dr. Touat has received research support from sanofi. |
| Rachna Malani, MD | Dr. Malani has nothing to disclose. |
| No disclosure on file | |
| Thierry Maisonobe | No disclosure on file |
| Dimitri Psimaras, MD | No disclosure on file |
| Timothee Lenglet, Jr., MD | No disclosure on file |
| Olivier Benveniste, MD, PhD | No disclosure on file |
| Aya M. Haggiagi, MD | No disclosure on file |